title: Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response.
authors: Department of Internal Medicine IV, University Hospital Halle, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
authors: Maxi
authors: M
authors: Wass
authors: Timo
authors: T
authors: Behlendorf
authors: Bärbel
authors: B
authors: Schädlich
authors: Anja
authors: A
authors: Mottok
authors: Andreas
authors: A
authors: Rosenwald
authors: Hans-Joachim
authors: HJ
authors: Schmoll
authors: Karin
authors: K
authors: Jordan
mesh_terms: D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000077547:Crizotinib; D017809:Fatal Outcome; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D017730:Ki-1 Antigen / Q000378:metabolism; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000378:metabolism*; D054353:Perforin / Q000378:metabolism; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism*; D012008:Recurrence; D053668:Syndecan-1 / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D017730:Ki-1 Antigen; D047428:Protein Kinase Inhibitors; D016271:Proto-Oncogene Proteins c-myc; D011720:Pyrazoles; D011725:Pyridines; D053668:Syndecan-1; D054353:Perforin; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases